표적 단백질 분해 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type (PROTAC, Molecular Glues), By Application (Drug Discovery, Therapy Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

표적 단백질 분해 시장 동향:

전 세계 표적 단백질 분해 시장 규모는 2024년 5억 4,440만 달러로 추정되며, 2025년부터 2030년까지 연평균 20.80%로 성장할 것으로 예상됩니다.

암, 신경 퇴행성 질환과 같은 만성질환의 빈도가 지속적으로 증가하고 있으며, 라이프스타일의 변화와 의료비 지출 증가로 인해 시장 성장이 가속화되고 있습니다. 이러한 질병의 높은 유병률은 새로운 치료 옵션에 대한 강력한 수요를 창출하여 시장 성장을 촉진하고 있습니다.

예를 들어, 세계보건기구(WHO) 자료에 따르면 2022년에는 약 2,000만 명이 새로 암 진단을 받고, 암 관련 사망자는 970만 명에 달했습니다. 또한, 암 진단을 받은 후 5년 이내에 암과 함께 살아가는 사람은 5,350만 명에 달할 것으로 추정됩니다.

이 분야의 R&D 활동의 확대는 큰 시장 성장 기회를 제공하고 있습니다. 예를 들어, 2023년 12월 오스트리아 과학재단(FWF)은 표적 단백질 분해 특별 연구 프로그램(SFB)을 4년간의 두 번째 지원 기간으로 승인했습니다. 표적 단백질 분해 특별 연구 프로그램(SFB)은 특정 단백질을 세포 분해의 표적으로 삼는 방법의 이해와 개발에 초점을 맞춘 연구 이니셔티브입니다. 이 프로그램은 최근 신약개발 및 치료적 개입에의 적용 가능성으로 인해 최근 큰 주목을 받고 있는 표적 단백질 분해 분야를 발전시키는 것을 목표로 하고 있습니다.

특히 FDA 및 EMA와 같은 기관의 간소화된 승인 프로세스와 같은 지원적인 규제 환경은 TPD 기반 치료법의 채택을 가속화하는 데 중요한 역할을 하고 있습니다. 기반 기술의 급속한 발전이 표적 단백질 분해 산업을 주도하고 있습니다. 단백질 분해 표적 키메라(PROTAC), 분자 접착제, 리소좀 표적 키메라(LYTACs)와 같은 혁신적인 접근법의 개발로 질병을 유발하는 단백질을 선택적으로 제거할 수 있는 TPD의 능력이 확대되었습니다. 이러한 기술적 혁신은 이전에는 치료할 수 없었던 단백질을 표적으로 삼을 수 있는 새로운 길을 열어 표적 단백질 분해 산업의 성장을 주도하고 있습니다.

이전에는 치료할 수 없었던 표적 단백질 분해의 치료적 가능성이 인식되고 있는 것이 표적 단백질 분해 산업의 주요 원동력이 되고 있습니다. 기존의 접근법은 조절이 어려운 단백질에 어려움을 겪는 경우가 많았지만, PROTAC(단백질 분해 표적 키메라)과 같은 기술은 질병을 유발하는 단백질의 분해를 촉진함으로써 유리한 해결책을 제공합니다. 이 방법은 암, 신경 퇴행성 질환 등의 치료에 큰 가능성을 보여주고 있어 이 분야에 대한 연구와 투자가 급증하고 있습니다. 미국 국립보건원(National Institute of Health)은 PROTACs를 최근 의약품 개발 기술의 대표주자로 꼽고 있습니다. 전임상 및 초기 임상시험의 성공이 증가함에 따라, 제약사와 생명공학 기업들은 치료 전략을 변화시킬 수 있는 잠재력을 인식하고 표적 단백질 분해를 파이프라인에 포함시키려 하고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 표적 단백질 분해 시장 : 변수, 동향, 범위

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 표적 단백질 분해 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 표적 단백질 분해 시장 : 종류별 추정·동향 분석

• 부문 대시보드
• 표적 단백질 분해 시장 : 종류별 변동 분석
• 표적 단백질 분해 시장 : 시장 규모 예측과 동향 분석, 종류별(2018-2030년)
• PROTAC
• 분자 접착제
• LYTAC
• 기타

제5장 표적 단백질 분해 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 표적 단백질 분해 시장 : 용도별 변동 분석
• 표적 단백질 분해 시장 : 시장 규모 예측과 동향 분석, 용도별(2018-2030년)
• Drug Discovery
• 치료법 개발
  • 암
  • 신경학
  • 감염증
  • 심혈관질환
  • 기타

제6장 표적 단백질 분해 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 표적 단백질 분해 시장 : 최종 용도별 변동 분석
• 표적 단백질 분해 시장 : 시장 규모 예측과 동향 분석, 최종 용도별(2018-2030년)
• 제약·바이오테크놀러지 기업
• 학술연구기관
• 병원· 임상 검사실

제7장 표적 단백질 분해 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁 분류
• 전략 매핑
• 기업 시장 상황 분석(2024년)
• 기업 개요/상장 기업
  • Bayer AG
  • Bio-Techne
  • BOC Sciences
  • BPS Bioscience, Inc.
  • BroadPharm
  • LifeSensors Inc.
  • MedChemExpress.
  • Merck KGaA
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.

ksm

영문 목차

영문목차

Targeted Protein Degradation Market Trends:

The global targeted protein degradation market size was estimated at USD 544.4 million in 2024 and is projected to grow at a CAGR of 20.80% from 2025 to 2030. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, are accelerating the market growth. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth.

For instance, data from the World Health Organization (WHO) indicates that in 2022, around 20 million individuals were newly diagnosed with cancer, and there were 9.7 million cancer-related deaths. It's estimated that 53.5 million people were living with cancer within five years after receiving their diagnosis.

The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in Targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• PROTAC
• Molecular Glues
• LYTACs
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Drug Discovery
• Therapy Development
  • Cancer
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Targeted Protein Degradation Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing frequency of chronic diseases
    • 3.2.1.2. Research and development activities
    • 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost
    • 3.2.2.2. Stringent regulations associated with approvals for novel TPD based therapies
• 3.3. Targeted Protein Degradation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Targeted Protein Degradation Market Type Movement Analysis
• 4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. PROTAC
  • 4.4.1. PROTAC market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Molecular Glues
  • 4.5.1. Molecular Glues market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. LYTACs
  • 4.6.1. LYTACs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Targeted Protein Degradation Market Application Movement Analysis
• 5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Drug Discovery market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Therapy Development
  • 5.5.1. Therapy Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Cancer
    • 5.5.2.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Neurology
    • 5.5.3.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Infectious Diseases
    • 5.5.4.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Cardiovascular Diseases
    • 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Others
    • 5.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Targeted Protein Degradation Market End Use Movement Analysis
• 6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospitals & Clinical Laboratories
  • 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Target disease prevalence
    • 7.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Target disease prevalence
    • 7.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Target disease prevalence
    • 7.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Target disease prevalence
    • 7.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Target disease prevalence
    • 7.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Target disease prevalence
    • 7.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Target disease prevalence
    • 7.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Target disease prevalence
    • 7.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Target disease prevalence
    • 7.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Target disease prevalence
    • 7.6.7.4. Regulatory framework
    • 7.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Target disease prevalence
    • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Target disease prevalence
    • 7.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Target disease prevalence
    • 7.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Bayer AG
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Bio-Techne
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. BOC Sciences
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. BPS Bioscience, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. BroadPharm
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. LifeSensors Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. MedChemExpress.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Merck KGaA
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Promega Corporation
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Thermo Fisher Scientific, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Type benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료